NASDAQ NMS - GLOBAL MARKET · PCVX

-0.38% · -$0.2259 · Vol 38.3K

Live · updated 10:21:43 ET

Vaxcyte Inc

Biotechnology

$59.99

Card

Relationship Map

Veridion Score

BETALOW CONF · 6/6 factors

Mon Aug 17 · last completed session · daily score · 12h old · PCVX

Methodology

PCVX

Vaxcyte Inc

Mon Aug 17 · last completed session · daily score · 12h old

58/100

NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

58/ 100

Veridion Score

NEUTRAL · LOW confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: LOW · 6/6 factors with data · Mon Aug 17 · last completed session · daily score · 12h old

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is PCVX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move PCVX next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 17
Score
Score moved +6
52/NEUTRAL -> 58/NEUTRAL
Veridion score historySource
May 13
CongressChecking access
Gilbert Ray Cisneros, Jr. purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
May 12
CongressChecking access
Gilbert Ray Cisneros, Jr. purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Apr 28
CongressChecking access
Gilbert Cisneros purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Apr 15
CongressChecking access
Gilbert Cisneros purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Apr 14
CongressChecking access
Gilbert Cisneros purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Mar 5
CongressChecking access
Jefferson Shreve sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 12
CongressChecking access
Christopher L. Jacobs sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Nov 8
CongressChecking access
Christopher L. Jacobs purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Vaxcyte Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

2020

Employees

507

Country

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$59.97

Day high

$60.86

Day low

$59.85

Previous close

$60.22

52W high